Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Amgen Tops Street 3rd-Quarter Profit and Revenue Forecasts

By AP | October 28, 2016

THOUSAND OAKS, Calif. (AP) — Amgen Inc. on Thursday reported third-quarter net income of $2.02 billion.

The Thousand Oaks, California-based company said it had profit of $2.68 per share. Earnings, adjusted for non-recurring costs, came to $3.02 per share.

The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of $2.79 per share.

The world’s largest biotech drugmaker posted revenue of $5.81 billion in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $5.74 billion.

Amgen earned $1.86 billion, or $2.44 per share, on revenue of $5.72 billion in the year-ago quarter.

Sales of the company’s top-seller, Enbrel, were flat at $1.45 billion as higher net selling price was offset by competition and unfavorable changes in inventory levels.

Further competition for Enbrel looms. During the quarter U.S. regulators approved the first near-copy, or biosimilar, of Enbrel called Erelzi, developed by Swiss drug giant Novartis. The anti-inflammatory drug, which is not yet being sold, was approved for the same indications as Enbrel, including rheumatoid arthritis, psoriasis and other immune system disorders.

Amgen now expects full-year earnings in the range of $11.40 to $11.55 per share, with revenue in the range of $22.6 billion to $22.8 billion. It previously expected to post annual adjusted earnings per share in the range of $11.10 to $11.40 with revenue in the range of $22.5 billion to $22.8 billion. Analysts surveyed by FactSet expect annual earnings per share of $11.36 on revenue of $22.77 billion.

Amgen shares have declined 1 percent since the beginning of the year, while the Standard & Poor’s 500 index has risen 4.7 percent. In after-hours trading, the stock shed about 1.5 percent to $158.10.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE